Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey

• Type of Material: Article
• Authors: Colin Swenson, Emory University; Nicole C. Lapinel, Louisiana State University; Juzar Ali, Louisiana State University
• Language: English
• Date: 2020-04-01
• Publisher: Oxford University Press Inc.
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1093/ofid/ofaa079
• Title of Journal or Parent Work: Open Forum Infectious Diseases
• Volume: 7
• Issue: 4
• Start Page: ofaa079
• End Page: ofaa079
• Grant/Funding Information: This work was supported by Insmed Incorporated, Bridgewater, New Jersey, USA.
• Keywords: Infectious Diseases; survey; Efficacy; ALIS; Phase-3; Science & Technology; Life Sciences & Biomedicine; Immunology; Infection; MAC lung disease; Tobramycin; Diagnosis; Safety; amikacin; Microbiology; tolerability; Randomized trial
• Research Categories: Health Sciences, Immunology; Biology, Microbiology; Health Sciences, Health Care Management

Abstract

Patients with Mycobacterium avium complex lung disease treated with amikacin liposome inhalation suspension (ALIS) at 2 clinics in the United States were surveyed to assess the frequency and management of ALIS-associated respiratory adverse events. Most respondents experienced these events, but management through physician-guided measures (eg, bronchodilator use, oral rinses, and/or temporary dosing adjustments) resulted in symptomatic improvement.